Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.
Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.
Prostate-specific antigen (PSA) screening was associated with similar decrease in incidence of advanced prostate cancer (PCa) among statin users vs nonusers, but less detection of low-grade localized tumours in the former than the latter — indicating that statin does not compromise the benefits of PSA-based screening while also conferring the benefit of less overdiagnosis of low-risk tumours.
In the treatment of older patients with essential hypertension, fimasartan alone or combined with hydrochlorothiazide demonstrates comparable safety and efficacy to perindopril monotherapy or in combination with indapamide, as shown in the results of a phase IIIb trial.
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.
Remnant cholesterol (C) appears predictive of mortality due to cardiovascular disease (CVD) among patients with type 2 diabetes (T2D), chronic kidney disease (CKD) stage 3 to 5, and incident diabetic nephropathy (DN), suggests a study.